143 related articles for article (PubMed ID: 32571711)
41. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
[TBL] [Abstract][Full Text] [Related]
42. Clinical Efficacy and Safety of Tacrolimus in Pakistani Living Donor Liver Transplant Recipients.
Azam F; Khan M; Bhatti ABH; Dar FS; Ahmad A; Javed N
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1048-1052. PubMed ID: 31659960
[TBL] [Abstract][Full Text] [Related]
43. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
[TBL] [Abstract][Full Text] [Related]
44. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
Felipe C; Tedesco-Silva H; Ferreira Brigido A; Bessa A; Ruppel P; Hiramoto L; de Paula M; Cristelli M; Stopa S; Mansur J; Viana L; Fahham L; Pepe C; Medina-Pestana J
Value Health Reg Issues; 2017 Dec; 14():108-115. PubMed ID: 29254534
[TBL] [Abstract][Full Text] [Related]
46. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients.
Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T
Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151
[TBL] [Abstract][Full Text] [Related]
47. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
48. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
Kälble F; Seckinger J; Schaier M; Morath C; Schwenger V; Zeier M; Sommerer C
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28581202
[TBL] [Abstract][Full Text] [Related]
49. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation.
Wu YJ; Lin YH; Yong CC; Li WF; Wang SH; Wang CC; Lin TL; Chen CL; Lin CC
Ann Transplant; 2016 Jan; 21():30-4. PubMed ID: 26782179
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Ettenger RB; Grimm EM
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
[TBL] [Abstract][Full Text] [Related]
51. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation.
Moreno M; Manzanares C; Castellano F; Medina E; Urruzuno P; Camarena C; Manzanares J; Jara P
Ther Drug Monit; 1998 Aug; 20(4):376-9. PubMed ID: 9712459
[TBL] [Abstract][Full Text] [Related]
52. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
[TBL] [Abstract][Full Text] [Related]
53. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
54. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
[TBL] [Abstract][Full Text] [Related]
55. De novo everolimus for recipients of kidney transplants from HLA identical donors.
Cristelli MP; Ferreira A; Hannun P; Felipe C; Aguiar W; Franco M; Tedesco-Silva H; Medina-Pestana J
J Bras Nefrol; 2016 Jun; 38(2):225-33. PubMed ID: 27438978
[TBL] [Abstract][Full Text] [Related]
56. Effect of everolimus rescue therapy for acute cellular rejection following pediatric living donor liver transplantation: Report of one case.
Hwang S; Namgoong JM; Oh SH; Kim KM; Ahn CS; Kwon H; Cho YJ; Kwon YJ
Ann Hepatobiliary Pancreat Surg; 2020 May; 24(2):216-220. PubMed ID: 32457270
[TBL] [Abstract][Full Text] [Related]
57. Living donor liver transplantation during the first 3 months of life.
Kasahara M; Sakamoto S; Sasaki K; Uchida H; Kitajima T; Shigeta T; Narumoto S; Hirata Y; Fukuda A
Liver Transpl; 2017 Aug; 23(8):1051-1057. PubMed ID: 28220684
[TBL] [Abstract][Full Text] [Related]
58. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
[TBL] [Abstract][Full Text] [Related]
59. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
